← Leaderboards
Tamar Taddei
Philadelphia Va Medical Center
$0
Attributed
$0
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2020–25$1$1$1$0$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 1
By mechanism
I01$0 · 1
Top collaborators
- David E Kaplan5 shared
Most similar at Philadelphia Va Medical Center
Same institution · by research overlap
- Amy Caroline Justice$51,314,210
- David E Kaplan$1,835,304
- Rudolph C Johnson$0
Others in their field
Other Emerging Leaders on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Yunda Huang · Fred Hutchinson Cancer Center$65,418,952
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Leonard Freedman · Leidos Biomedical Research, Inc.$20,851,347
- Kristin Aillon · Midwest Research Institute$18,958,174
Research focus
Exposure ToFollow-UpDouble-Blind MethodEndothelial DysfunctionEncephalopathiesFibrosisAlcoholsAdverse OutcomeAscitesCost SavingsAbdomenCaringCessation Of LifeCholesterolChronicChronic Liver DiseaseChronic Viral HepatitisBilirubinCirrhosisClinical EfficacyClinically SignificantCardiovascular SystemCostFostering
Grant awards (5)
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2025 · VA
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2024 · VA
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2023 · VA
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2022 · VA
Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis$0
I01 · FY2020 · VA